Ken Griffin Eagle Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.71 - $6.07 $3,339 - $5,463	900 New	900 $3,000
Q1 2024 May 15, 2024	SELL	$4.26 - $6.51 $8,520 - $13,020	-2,000 Reduced 40.0%	3,000 $15,000
Q4 2023 Feb 14, 2024	BUY	$4.63 - $15.21 $16,668 - $54,756	3,600 Added 257.14%	5,000 $26,000
Q3 2023 Nov 14, 2023	SELL	$15.21 - $22.88 $22,815 - $34,320	-1,500 Reduced 51.72%	1,400 $22,000
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $21,287 - $38,244	1,200 Added 70.59%	2,900 $56,000
Q1 2023 May 15, 2023	SELL	$25.06 - $34.09 $1.46 Million - $1.99 Million	-58,400 Reduced 97.17%	1,700 $48,000
Q4 2022 Feb 14, 2023	SELL	$24.98 - $39.77 $1.89 Million - $3.01 Million	-75,600 Reduced 55.71%	60,100 $1.76 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $3.59 Million - $6.39 Million	135,700 New	135,700 $3.59 Million

8.35M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $10.4M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.